Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

1.474 -0.046 (-3.06%)
Streaming Delayed Price Updated: 10:22 AM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protalix BioTherapeutics, Inc. (DE) Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Preview: Protalix BioTherapeutics's Earnings
 
Via Benzinga
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday! 
Via InvestorPlace
Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil
 
Via Benzinga
Earnings Preview For Protalix BioTherapeutics
 
Via Benzinga
Looking Into Protalix BioTherapeutics's Return On Capital Employed
 
Via Benzinga
Protalix BioTherapeutics Well Placed to Advance in 2023
We see a number of reasons to be positive about PLX shares in 2023 and investors should take note. 
Via Talk Markets
Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket
Gainers Lucira Health, Inc. (NASDAQ: LHDX) rose 228.5% to $0.46 in pre-market trading after the FDA authorized Lucira's over-the-counter at-home test to detect both influenza and COVID-19 viruses. 
Via Benzinga
$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
By David Willey, Benzinga 
Via News Direct
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License... 
Via TheNewswire.com
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
Protalix PRX-102: Likely Approval Could Be A Game Changer
Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results. 
Via Talk Markets
Why Protalix Is Back On The Radar?
After encountering bureaucratic hurdles, Protalix's PRX-102 has come through the BALANCE study with flying colors and is ready to reapply for its BLA. 
Via Talk Markets
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial
 
Via Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, 
Via Benzinga
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... 
Via TheNewswire.com
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
By Mark Gilman, Benzinga 
Via News Direct
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... 
Via Benzinga
10 Most-Searched Tickers On Benzinga Pro In April: Musk Mania, Apple Drops, Several Newcomers Move Up
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the... 
Via Benzinga
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
Via Benzinga
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
68 Biggest Movers From Yesterday
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares... 
Via Benzinga
Why Protalix BioTherapeutics Stock Is Soaring
Protalix BioTherapeutics Inc (AMEX:PLX) shares are surging Monday after the company said its Phase 3 trial for the treatment of Fabry disease met its primary endpoint. Fabry disease is an inherited... 
Via Benzinga
Protalix BioTherapeutics's Return On Capital Employed Insights
Benzinga Pro data, Protalix BioTherapeutics (AMEX:PLX) reported Q4 sales of $8.55 million. Earnings fell to a loss of $6.67 million, resulting in a 58.78% decrease from last quarter. 
Via Benzinga
Recap: Protalix BioTherapeutics Q4 Earnings
  Protalix BioTherapeutics (AMEX:PLX) reported its Q4 earnings results on Thursday, March 31, 2022 at 06:50 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS